References
- Woodman CB, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7;11-22, 2007 https://doi.org/10.1038/nrc2050
- zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2;342-350, 2002 https://doi.org/10.1038/nrc798
- Tindle RW: Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2;59-65, 2002 https://doi.org/10.1038/nrc700
- Roden R, Wu TC: How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6;753-763, 2006 https://doi.org/10.1038/nrc1973
- Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Muller-Holzner E, Pawlita M, Pfister H, Fritsch P: Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 356;1985-1986, 2000 https://doi.org/10.1016/S0140-6736(00)03315-8
- Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D: Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11;4717-4723, 2005 https://doi.org/10.1158/1078-0432.CCR-04-2599
- Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F, Guimaraes V, Rabot S, Alcocer-Gonzalez JM, Gratadoux JJ, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, Gruss A, Langella P: A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175;7297-7302, 2005 https://doi.org/10.4049/jimmunol.175.11.7297
- Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC: Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-rumor immunity. Gene Ther 7;726-733, 2000
- Kim TW, Hung CF, Boyd D, Juang J, He L, Kim JW, Hardwick JM, Wu TC: Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 171;2970-2976, 2003 https://doi.org/10.4049/jimmunol.171.6.2970
- Lin CT, Tsai YC, He L, Calizo R, Chou HH, Chang TC, Soong YK, Hung CF, Lai CH: A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci 13;481-488, 2006 https://doi.org/10.1007/s11373-006-9086-6
- Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW: Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70;960-965, 1996
- Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5;296-306, 2005 https://doi.org/10.1038/nri1592
- Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392;245-252, 1998 https://doi.org/10.1038/32588
- Schultze JL, Grabbe S, von Bergwelt-Baildon MS: DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol;25:659-664, 2004 https://doi.org/10.1016/j.it.2004.09.016
- Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF: Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells. Clin Exp Immunol 139;458-467, 2005 https://doi.org/10.1111/j.1365-2249.2005.02733.x
- Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR: B cells directly tolerize CD8(+) T cells. J Exp Med 188;1977-1983, 1998 https://doi.org/10.1084/jem.188.11.1977
- Eynon EE, Parker DC: Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175;131-138, 1992 https://doi.org/10.1084/jem.175.1.131
- Raimondi G, Zanoni I, Citterio S, Ricciardi-Castagnoli P, Granucci F: Induction of peripheral T cell tolerance by antigen-presenting B cells. I. Relevance of antigen presentation persistence. J Immunol 176;4012-4020, 2006 https://doi.org/10.4049/jimmunol.176.7.4012
- Rodriguez-Pinto D: B cells as antigen presenting cells. Cell Immunol 238;67-75, 2005 https://doi.org/10.1016/j.cellimm.2006.02.005
- Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, Tanimoto M, Harada M, Takahashi T, Akatsuka Y: Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 169;2164-2171, 2002 https://doi.org/10.4049/jimmunol.169.4.2164
- Zentz C, Wiesner M, Man S, Frankenberger B, Wollenberg B, Hillemanns P, Zeidler R, Hammerschmidt W, Moosmann A: Activated B cells mediate efficient expansion of rare antigen-specific T cells. Hum Immunol 68;75-85, 2007 https://doi.org/10.1016/j.humimm.2006.12.004
- Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH, Kang CY: CD1d-restricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 66;6843-6850, 2006 https://doi.org/10.1158/0008-5472.CAN-06-0889
- Gallo P, Dharmapuri S, Cipriani B, Monaci P: Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther; 12 Suppl 1;S84-91, 2005 https://doi.org/10.1038/sj.gt.3302619
- Xia D, Moyana T, Xiang J: Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 16;241-259, 2006 https://doi.org/10.1038/sj.cr.7310032
- Lyakh LA, Koski GK, Young HA, Spence SE, Cohen PA, Rice NR: Adenovirus type 5 vectors induce dendritic cell differentiation in human CD 14(+) monocytes cultured under serum-free conditions. Blood 99;600-608, 2002 https://doi.org/10.1182/blood.V99.2.600
- Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfield LH, Dorsky DI, Economou JS, Mukherji B, Chakraborty NG: Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology 113;472-481, 2004 https://doi.org/10.1111/j.1365-2567.2004.01978.x
- Jin HT, Youn JI, Kim HJ, Lee JB, Ha SJ, Koh JS, Sung YC: Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. Hum Gene Ther 16;328-338, 2005 https://doi.org/10.1089/hum.2005.16.328
- Germain RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76;287-299, 1994 https://doi.org/10.1016/0092-8674(94)90336-0
- Petry KU, Scheffel D, Bode U, Gabrysiak T, Kochel H, Kupsch E, Glaubitz M, Niesert S, Kuhnle H, Schedel I: Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 57;836-840, 1994 https://doi.org/10.1002/ijc.2910570612
- Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3; 133-146, 2003 https://doi.org/10.1038/nri1001